Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What fueled the previous growth in the alpha mannosidosis market?

In recent times, the market size for alpha mannosidosis has experienced a swift expansion. The market is projected to increase from $15.1 billion in 2024 to $18.02 billion in 2025, with a compound annual growth rate (CAGR) of 19.3%. This significant growth during the historical period can be credited to factors such as the growth of emerging markets, urbanization, a rise in the demand for synthetic fibers, and government policies supporting the textile industry.

What will be the alpha mannosidosis market size in the future?

The market size for alpha mannosidosis is projected to witness swift expansion in the forthcoming years. It is estimated to reach $34.52 billion by 2029 with a compound annual growth rate (CAGR) of 17.6%. Such growth in the prediction period can be ascribed to factors such as global population expansion and urbanization, the rise of e-commerce, growing demand for sportswear, heightened presence of organized retail in emergent economies, and an uptick in social media penetration. Noteworthy trends anticipated within this period encompass an escalation in the utilization of enzyme therapy, the acceptance of hematopoietic stem cell transplantation, and the adoption of cisterna magna infusion.

Get your alpha mannosidosis market report here!

https://www.thebusinessresearchcompany.com/report/alphas-mannosidosis-global-market-report

What main drivers are fueling expansion in the alpha mannosidosis market?

The growing need for precision medicine is anticipated to drive the expansion of the alpha mannosidosis market. Precision medicine is a healthcare approach that is tailored to individual differences in patients’ genes, environments, and lifestyles to enhance treatment and prevention methods. The increase in precision medicine is bolstered by advancements in genomic technologies and data analytics, enabling more accurate identification of genetic variants and their health impacts. Also, the rising demand for personalized treatment selections, coupled with the growing cognizance of the shortcomings of generalized approaches, has increased interest in customized healthcare solutions. Precision medicine bolsters the creation of targeted therapies tailored for specific genetic mutations and patient profiles related to this rare condition. For instance, in February 2024, data from the Personalized Medicine Coalition (PMC), a U.S.-based nonprofit umbrella organization reported that in 2023, the FDA approved 16 new tailored treatments for rare diseases, marking a significant increase from just six approvals in 2022. Hence, the growing need for precision medicine is propelling the alpha mannosidosis market’s growth.

What key areas define the segmentation of the global alpha mannosidosis market?

The alpha mannosidosis market covered in this report is segmented –

1) By Therapy Type: Bone Marrow Transplant (BMT), Enzyme Replacement Therapy (ERT), Other Therapies

2) By Indication: Type I, Type II, Type III

3) By End-User: Hospitals, Speciality Clinics

Subsegments:

1) By Bone Marrow Transplant (BMT): Autologous BMT, Allogeneic BMT

2) By Enzyme Replacement Therapy (ERT): Recombinant Enzymes, Long-acting Enzyme Formulations

3) By Other Therapies: Symptomatic Treatments, Gene Therapy, Supportive Care

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=4093&type=smp

Who are the dominant players expanding their reach in the alpha mannosidosis market?

Major companies operating in the alpha mannosidosis market include Chiesi Farmaceutici S.p.A., Cipla, Daiichi Sankyo Company, Ultragenyx Pharmaceutical Inc, Mitsubishi Tanabe Pharma, Merck, Bristol-Myers Squibb, Novartis AG, Amgen, Centogene, Zymenex A/S, Albumedix Ltd, Kite Pharma, Catalent, Freeline Therapeutics, Avectas, DiNAQOR AG, Vivet Therapeutics, Allergan, PsiOxus Therapeutics, Herantis Pharma Plc, Biocad, Celgene Corporation, Johnson & Johnson, F. Hoffmann-La Roche Ltd, Eli Lilly and Company, Bayer AG, PTC Therapeutics, Gilead Sciences Inc., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Pfizer S.R.L., AstraZeneca plc, Biogen SA, Sanofi, Adcock Ingram

How are evolving market trends shaping alpha mannosidosis Strategies?

The alpha mannosidosis market’s major corporations are prioritizing the design of an enzyme replacement therapy for rare alpha-mannosidosis. The contribution of exogenous alpha-mannosidase in enzyme replacement therapy also reduces the upsurge of mannose-rich oligosaccharides in multiple organs and tissues. The accumulation of these substances is a distinct trait of alpha-mannosidosis, leading to significant pathological impacts. For example, in February 2023, US-based pharmaceutical firm, Chiesi Global Rare Diseases, introduced Lamzede (velmanase alfa); this is the inaugural enzyme replacement therapy approved in the US to treat alpha-mannosidosis. A condition where the body lacks the enzyme alpha-mannosidase. Symptoms extend beyond the central nervous system and Lamzede, counteracting the deficiency, works similarly to the body’s alpha-mannosidase enzyme, reinstating normal cellular activity. Patients receive a 10 mg Lamzede injection once a week.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=4093

Which regions are emerging as leaders in the alpha mannosidosis market?

North America was the largest region in the alpha mannosidosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the alpha mannosidosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Cell and Gene Therapy Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cell-and-genes-therapy-global-market-report

Gene Therapy Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report

Stem Cell Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/stem-cell-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: